Table 1.
Whole population and subgroups stratified based on agreement between pEDSS and gmEDSS; demographic and clinical feature
| Total (n = 243) | pEDSS = gmEDSS (n = 169) | pEDSS < gmEDSS (n = 32) | pEDSS > gmEDSS (n = 42) | ||||
|---|---|---|---|---|---|---|---|
| Variable | P value | ||||||
| Sex | |||||||
| Female (n; %) | 173,00 (71,19) | 118 (69,82) | 24 (75%) | 31 (73.81) | 0.771 | ||
| Male (n; %) | 70,00 (28,81) | 51 (30,18) | 8 (25%) | 11 (26.19) | |||
| Age | |||||||
| Mean, sd | 39,77 (12,35) | 37,46 (12,14) | 45.03 (12.16) | 45.02 + 10.60 | < 0.001 | ||
| Median (Q1-Q3) | 39 (30–48) | 37 (27–45) | 45,5 (37,5–47,5) | 44 (39–51) | |||
| Disease type | |||||||
| CIS (n; %) | 1,00 (0,41) | 1 (0,59) | 0 (0) | 0 (0) | < 0.001 | ||
| RR (n; %) | 210,00 (86,78) | 156 (92,31) | 20 (62,50) | 34 (82,93) | |||
| SP (n; %) | 23,00 (9,09) | 10 (5,92) | 7 (21,88) | 5 (12,20) | |||
| PP (n; %) | 9,00 (3,72) | 2 (1,18) | 5 (15,62) | 2 (4,88) | |||
| Disease duration | |||||||
| mean, sd | 9,60 (7,83) | 8,68 (6,70) | 9.78 (10.28) | 13,16 (9,01) | 0.007 | ||
| median (Q1-Q3) | 7 (3–13) | 7 (3–12) | 5,5 (3–13) | 11 (6.8 -18.3) | |||
| Ongoing therapy | |||||||
| GA (n; %) | 19,00 (7,82) | 13 (7,69) | 3 (9,38) | 3 (7.14) | |||
| INF (n; %) | 51,00 (20,99) | 38 (22,49) | 7 (21,88) | 6 (14.29) | |||
| DMF (n; %) | 52,00 (21,40) | 39 (23,08) | 5 (15,62) | 8 (19.05) | |||
| TRF (n; %) | 16,00 (6,58) | 6 (3,55) | 6 (18,75) | 4 (9.52) | |||
| FTY (n; %) | 46,00 (18,93) | 37 (21,89) | 0 (0) | 9 (21.43) | |||
| NTZ (n; %) | 36,00 (14,81) | 25 (14,79) | 4 (12,50) | 7 (16.67) | |||
| ALZ (n; %) | 10,00 (4,12) | 5 (2,96) | 4 (12,50) | 1 (2.38) | |||
| None (n; %) | 13,00 (5,35) | 6 (3,55) | 3 (9,38) | 4 (9.52) | |||
| FSS | |||||||
| mean, sd | 30,63 (16,09) | 26.68 (14.27) | 39.65625 (17.80) | 39,61 (15,60) | < 0.001 | ||
| median (Q1-Q3) | 30 16–43 | 24 (14–37) | 44,5 (21–55,5) | 38 (30–53) | |||
| PHQ9 | |||||||
| mean, sd | 7,52 (6,07) | 5.86 (4.92) | 11.1875 (7.168198) | 11.35714 (6.49135) | < 0.001 | ||
| median (Q1-Q3) | 6 (3–11) | 5 (2–8) | 12 (5–15,5) | 11.5 (5–16) | |||
| pEDSS | |||||||
| < = 3,5 (n; %) | 142 (58.68) | 130 (76,92) | 11 (34,38) | 1 (2,44) | < 0.001 | ||
| > = 4 (n; %) | 101 (41.32) | 39 (23,08) | 21 (65.62) | 41 (97,56) | |||
GA glatiramer acetate, INF interferon, DMF dimethyl fumarate, TRF teriflunomide, FTY fingolimod, NTZ natalizumab, ALZ alemtuzumab, EDSS Expanded Disability Status Scale, pEDSS perceived EDSS, gmEDSS Google EDSS, FSS Fatigue Severity Scale, PHQ-9 Patient Health Questionnaire-9